髓系来源生长因子通过维持心肌细胞SERCA2a表达保护压力负荷诱导的心力衰竭
本研究探讨了髓系来源生长因子(MYDGF)在压力负荷诱导的心力衰竭中的作用。在横向主动脉缩窄小鼠模型及严重主动脉瓣狭窄患者中,MYDGF水平升高;Mydgf缺失加重左室肥厚和收缩功能障碍,而骨髓来源炎症细胞过表达MYDGF或给予重组MYDGF可减轻肥厚和功能障碍并改善生存。机制上MYDGF通过增强PIM1表达和活性上调SERCA2a,改善钙循环和肌节功能。
要点
- MYDGF在压力负荷后由单核/巨噬细胞分泌,代偿性保护心脏。
- MYDGF通过PIM1上调SERCA2a,改善钙循环和收缩功能。
- 重组MYDGF治疗可减轻小鼠左室肥厚和功能障碍并改善生存。
核心结论
- MYDGF介导炎症细胞与心肌细胞间的适应性串话,保护压力负荷诱导的心力衰竭。
研究设计与样本
- 研究使用野生型、Mydgf基因敲除、骨髓嵌合或骨髓条件性转基因小鼠,行横向主动脉缩窄术诱导压力负荷心力衰竭。
- 通过靶向液相色谱-质谱法测量血浆MYDGF浓度,用磷酸化蛋白质组学和基于底物的激酶活性推断鉴定信号靶点。
- 在分离的心肌细胞中记录钙瞬变和肌节收缩,并探索重组MYDGF的治疗潜力。
主要发现
- 压力负荷后小鼠左室心肌和血浆中MYDGF蛋白丰度增加;严重主动脉瓣狭窄患者血浆MYDGF浓度升高,经导管主动脉瓣植入后下降。
- Mydgf-/-小鼠基线无表型,但压力负荷后左室肥厚和收缩功能障碍较野生型更严重;骨髓来源炎症细胞条件性过表达MYDGF则减轻肥厚和功能障碍。
- 机制上MYDGF通过增强PIM1表达和活性抑制G蛋白偶联受体激动剂诱导的肥厚并上调SERCA2a;压力负荷的Mydgf-/-小鼠心肌细胞PIM1和SERCA2a表达降低,肥厚加重,钙循环和肌节功能受损。
- 移植野生型骨髓细胞或腺病毒Serca2a基因转移可改善压力负荷Mydgf-/-小鼠的心脏功能;皮下注射重组MYDGF可增强SERCA2a表达、减轻左室肥厚和功能障碍并改善生存。
临床怎么用
- MYDGF及其下游PIM1-SERCA2a通路可能成为压力负荷性心力衰竭的潜在治疗靶点。
- 重组MYDGF或SERCA2a基因转移在动物模型中显示治疗潜力,但尚未在临床验证。
局限性
- 研究主要基于小鼠模型和离体细胞实验,人体数据仅限于观察性血浆浓度变化。
- MYDGF的长期安全性和临床疗效尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation contributes to the pathogenesis of heart failure, but there is limited understanding of inflammation's potential benefits. Inflammatory cells secrete MYDGF (myeloid-derived growth factor) to promote tissue repair after acute myocardial infarction. We hypothesized that MYDGF has a role in cardiac adaptation to persistent pressure overload. METHODS: We defined the cellular sources and function of MYDGF in wild-type (WT), Mydgf-deficient (Mydgf-/-), and Mydgf bone marrow-chimeric or bone marrow-conditional transgenic mice with pressure overload-induced heart failure after transverse aortic constriction surgery. We measured MYDGF plasma concentrations by targeted liquid chromatography-mass spectrometry. We identified MYDGF signaling targets by phosphoproteomics and substrate-based kinase activity inference. We recorded Ca2+ transients and sarcomere contractions in isolated cardiomyocytes. Additionally, we explored the therapeutic potential of recombinant MYDGF. RESULTS: MYDGF protein abundance increased in the left ventricular myocardium and in blood plasma of pressure-overloaded mice. Patients with severe aortic stenosis also had elevated MYDGF plasma concentrations, which declined after transcatheter aortic valve implantation. Monocytes and macrophages emerged as the main MYDGF sources in the pressure-overloaded murine heart. While Mydgf-/- mice had no apparent phenotype at baseline, they developed more severe left ventricular hypertrophy and contractile dysfunction during pressure overload than WT mice. Conversely, conditional transgenic overexpression of MYDGF in bone marrow-derived inflammatory cells attenuated pressure overload-induced hypertrophy and dysfunction. Mechanistically, MYDGF inhibited G protein-coupled receptor agonist-induced hypertrophy and augmented SERCA2a (sarco/endoplasmic reticulum Ca2+-ATPase 2a) expression in cultured neonatal rat ventricular cardiomyocytes by enhancing PIM1 (Pim-1 proto-oncogene, serine/threonine kinase) expression and activity. Along this line, cardiomyocytes from pressure-overloaded Mydgf-/- mice displayed reduced PIM1 and SERCA2a expression, greater hypertrophy, and impaired Ca2+ cycling and sarcomere function compared with cardiomyocytes from pressure-overloaded WT mice. Transplanting Mydgf-/- mice with WT bone marrow cells augmented cardiac PIM1 and SERCA2a levels and ameliorated pressure overload-induced hypertrophy and dysfunction. Pressure-overloaded Mydgf-/- mice were similarly rescued by adenoviral Serca2a gene transfer. Treating pressure-overloaded WT mice subcutaneously with recombinant MYDGF enhanced SERCA2a expression, attenuated left ventricular hypertrophy and dysfunction, and improved survival. CONCLUSIONS: These findings establish a MYDGF-based adaptive crosstalk between inflammatory cells and cardiomyocytes that protects against pressure overload-induced heart failure.
引用
- Korf-Klingebiel M, Reboll MR, Polten F, et al. Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca2+-ATPase Expression in Cardiomyocytes. Circulation. 2021. PMID: 34372689. doi:10.1161/CIRCULATIONAHA.120.053365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。